Accessibility Menu
BioStem Technologies logo

BioStem Technologies(NASDAQ) BSEM

Market Cap$59.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year+210%
1 Year-48%
1 Month-14%
$3.70
+10.52%
+0.35Today
BioStem Technologies last closing stock price
MetricPriceDate
Last closeUSD 3.352026-08-19
BioStem Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.97%USD 3.802026-08-12
1 month-14.01%USD 3.892026-07-20
3 month-18.41%USD 4.102026-05-21
Year to date-12.2%USD 3.812025-12-31
1 year-48.38%USD 6.482025-08-19
3 year+132.7%USD 1.442023-08-18
5 year+209.72%USD 1.082021-08-19
Since inception-99.62%USD 877.192003-08-04

BioStem Technologies Financials at a Glance

Market Cap

$59.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$60.31M

Net Income (TTM)

-$28.29M

EPS (TTM)

-$1.68

P/E Ratio

-1.99

Dividend

$0.00

Beta (Volatility)

0.47 (Low)

Price

$3.70

Volume

110,489.333

Open

$3.51

Previous Close

$3.35

Daily Range

$3.51 - $3.86

52-Week Range

$2.25 - $8.40

Estimated Earnings Date

Nov 12, 2026

BSEM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioStem Technologies

BioStem Technologies, Inc. is a biotechnology company focused on the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies. Based in Fort Lauderdale, Florida, the company offers innovative solutions aimed at improving patient outcomes in the healthcare sector.

Products and Services
  • Vendaje: A structural tissue allograft for soft tissue wound protection
  • American Amnion: A human connective tissue matrix for homologous use
  • Vendaje OPTIC: An allograft for ocular surface repair
Growth Outlook
  • Recent quarterly revenue reached $6.14 million, indicating strong market demand
  • Trailing twelve months (TTM) revenue shows a significant increase compared to previous periods
  • Expansion into new markets is anticipated to drive future growth
Financial Highlights
  • Net income for the latest quarter was -$8.82 million, reflecting ongoing investment in growth
  • Cash and cash equivalents stood at $13.70 million, providing liquidity for operations
  • Gross profit margin for the latest quarter was 52.47%, showcasing operational efficiency
BioStem Technologies, Inc. operates in a dynamic sector with a focus on innovative healthcare solutions. The company's product offerings are designed to address critical needs in wound care and regenerative medicine, positioning it well for future growth. Recent financial performance indicates a commitment to expanding market presence, despite current net losses. The strong gross profit margin suggests effective cost management, while the available cash reserves provide a buffer for ongoing operations and strategic initiatives. As the company continues to innovate and expand, it may attract interest from investors looking for opportunities in the biotechnology space.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

24

CEO

Jason Matuszewski

Website

www.biostemtechnologies.com

Headquarters

Fort Lauderdale, FL 33309, US

BSEM Financials

Key Financial Metrics (TTM)

Gross Margin

112.77%

Operating Margin

38.70%

Net Income Margin

46.91%

Return on Equity

-76.13%

Return on Capital

-1.62%

Return on Assets

-57.95%

Earnings Yield

-50.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$59.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.83M

Volume

110.49K

Avg. Volume

69.35K

Financials (TTM)

Gross Profit

-$68.01M

Operating Income

-$23.34M

EBITDA

-$21.95M

Operating Cash Flow

-$5.92M

Capital Expenditure

-$2.91M

Free Cash Flow

-$8.83M

Cash & ST Invst.

$6.96M

Total Debt

$1.22M

BioStem Technologies Performance Analysis

BioStem Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 6,875,20258.4%
20232023-12-31USD 16,685,405142.7%
20242024-12-31USD 69,658,420317.5%
20252025-12-31USD 47,482,015-31.8%
BioStem Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-78.8%
Q42025-12-31-909.8%
Q12026-03-31107.2%
Q22026-06-3028.7%
BioStem Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.63327.6%
20232023-12-31USD -0.62-1.9%
20242024-12-31USD 1.43N/A
20252025-12-31USD -0.39N/A
BioStem Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30243.9%
Q42025-12-31-2142.7%
Q12026-03-3122.4%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$7.90M

-84.0%

Gross Profit

$4.84M

-90.0%

Gross Margin

61.28%

N/A

Market Cap

$59.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$817.13K

N/A

Employees

73

N/A

Net Income

-$8.97M

-1489.7%

EBITDA

-$7.66M

-4513.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.96M

-77.4%

Total Debt

$1.22M

-65.9%

Accounts Receivable

$6.62M

-90.2%

Inventory

$4.71M

+91.5%

Long Term Debt

$2.71K

-99.3%

Short Term Debt

$1.22M

-62.1%

Return on Assets

-57.95%

N/A

Return on Invested Capital

-84.50%

N/A

Free Cash Flow

-$5.59M

-209.9%

Operating Cash Flow

-$5.54M

-202.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VICPVicapsys Life Sciences, Inc.
$1.45+0.00%
PRNAFAlterity Therapeutics Limited
$0.35+0.00%
IUGNFImugene Limited
$0.07-9.12%
ZIVOZIVO Bioscience, Inc.
$3.95-2.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.83+0.06%
IBITiShares Bitcoin Trust
$41.19+0.06%
SPCXSpace Exploration Technologies
$130.74-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.82-0.04%

Questions About BSEM

What is the current price of BioStem Technologies?

BioStem Technologies is trading at $3.70 per share.

What is the 52-week range for BioStem Technologies?

Over the past 52 weeks, BioStem Technologies has traded between $2.25 and $8.40.

How much debt does BioStem Technologies have?

As of the most recent reporting period, BioStem Technologies reported total debt of $1.22M.

How much cash does BioStem Technologies have on hand?

BioStem Technologies reported $6.96M in cash and cash equivalents in its most recent financial results.

What is BioStem Technologies’s dividend yield?

BioStem Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services